ライフサイエンスコーパス: pertussis vaccine

1 id, reduced diphtheria toxoid, and acellular pertussis vaccine).

2 components other than those included in the pertussis vaccine.

3 ndomized, double-blind trial of an acellular pertussis vaccine.

4 present since the introduction of acellular pertussis vaccine.

5 f booster doses of diphtheria-tetanus toxoid-pertussis vaccine.

6 id, reduced diphtheria toxoid, and acellular pertussis vaccine.

7 diphtheria and tetanus toxoids and acellular pertussis vaccine.

8 the potential of Qbeta-glycan as a new anti-pertussis vaccine.

9 ectiveness each year after the final dose of pertussis vaccine.

10 to compare protection provided by different pertussis vaccines.

11 defects in immunity stimulated by acellular pertussis vaccines.

12 ella, hepatitis B, varicella, influenza, and pertussis vaccines.

13 elopment of the next generation of acellular pertussis vaccines.

14 ified form PTd, is an important component of pertussis vaccines.

15 nses might improve the efficacy of acellular pertussis vaccines.

16 ella pertussis might have on the efficacy of pertussis vaccines.

17 ponses, which may correlate with efficacy of pertussis vaccines.

18 celerate early life immunity by acellular B. pertussis vaccines.

19 der people: influenza and tetanus-diphtheria-pertussis vaccines.

20 entify potential targets for next-generation pertussis vaccines.

21 irculation and underestimating the impact of pertussis vaccines.

22 tussis can hamper infant immune responses to pertussis vaccines.

23 s after high childhood coverage of acellular pertussis vaccines.

24 dies assessing the duration of protection of pertussis vaccines.

25 the transition from whole-cell to acellular pertussis vaccines.

26 d to the lack of cross protection induced by pertussis vaccines.

27 r high, there is an urgent need for new anti-pertussis vaccines.

28 ly aid in the development of next-generation pertussis vaccines.

29 main in understanding the immune response to pertussis vaccines.

30 eria; and tetanus, diphtheria, and acellular pertussis vaccines.

31 tetanus and diphtheria toxoids and acellular pertussis vaccines.

32 adult tetanus, reduced diphtheria, acellular pertussis) vaccine.

33 diphtheria and tetanus toxoids and acellular pertussis vaccine 10 years ago, during adolescence.

34 diphtheria and tetanus toxoids and acellular pertussis vaccine (31.3%).

35 id, reduced diphtheria toxoid, and acellular pertussis vaccine; 31.6% vs. 32.7%, respectively; P = .8

36 50 or later who may have received whole-cell pertussis vaccine (53%; -11% to 80%); p-heterogeneity=0.

37 50 or later who may have received whole-cell pertussis vaccine (53%; -11-80%) (P-heterogeneity = 0.9)

38 having received an age-appropriate number of pertussis vaccines (AAV) (for persons aged >/=3 months)

39 pertussis protein included in new acellular pertussis vaccines (ACPVs), a series of monoclonal antib

40 The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter

41 doses of the diphtheria, tetanus toxoid, and pertussis vaccine administered (0.9%; 0.5-1.3%).

42 erage and timing of diphtheria, tetanus, and pertussis vaccine administration and various age-restric

43 id, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) in healthy, nonpregnan

44 Booster doses of acellular pertussis vaccine after 7 years of age may be an effecti

45 r coexistence and the limited efficacy of B. pertussis vaccines against B. parapertussis suggest a la

46 This trial of an acellular pertussis vaccine among adolescents and adults evaluated

47 deration should be given to use of acellular pertussis vaccines among school-aged children.

48 e 2781 subjects, 1391 received the acellular pertussis vaccine and 1390 received the control vaccine.

49 No association was found between pertussis vaccine and any allergic outcome based on a si

50 mps/rubella vaccine or thimerosal-containing pertussis vaccine and autism is evident.

51 Baboons receiving acellular pertussis vaccine and infants born to mothers vaccinated

52 trations, but blunts subsequent responses to pertussis vaccine and some CRM-conjugated antigens.

53 ul for the construction of more well-defined pertussis vaccines and for the interpretation of human s

54 een linked to switch to the use of acellular pertussis vaccines and the evolution of Bordetella pertu

55 d short-lived immunity elicited by acellular pertussis vaccines and to their inability to prevent nas

56 March 1996 (before introduction of acellular pertussis vaccine) and between April 1998 and March 2000

57 It is a primary component of acellular pertussis vaccines, and anti-PRN antibody titers correla

58 -cell pertussis vaccines, OPV and whole-cell pertussis vaccines, and OPV and acellular pertussis vacc

59 ertussis toxin, a critical component of many pertussis vaccines, and to examine the effects of such d

60 Concentrations of anti-pertussis vaccine antibodies were measured by standardiz

61 ation, geometric mean concentrations of anti-pertussis vaccine antibodies were significantly lower in

62 ; 95% CI, 5.38-12.50), or tetanus-diphtheria-pertussis vaccine (AOR, 6.86; 95% CI, 3.79-13.10).

63 rotection contrasted with a solely acellular pertussis vaccine (aP) series.

64 cularly in populations primed with acellular pertussis vaccines (aP).

65 tion program of the currently used acellular pertussis vaccine (aPV).

66 Whole cell pertussis vaccines are generally highly efficacious.

67 dence that the currently available acellular pertussis vaccines are not providing optimal control of

68 Acellular pertussis (aP) and whole-cell (wP) pertussis vaccines are presumed to have similar short-te

69 ted influenza, tetanus toxoid, and acellular pertussis vaccines are recommended during pregnancy.

70 rogram in the United States, where acellular pertussis vaccines are recommended for infants.

71 tetanus and diphtheria toxoids and acellular pertussis vaccines are reviewed in this second of two ar

72 ir widespread use, increasing concerns about pertussis vaccine-associated adverse events led the deve

73 Baboons were vaccinated with acellular pertussis vaccine at 2 days of age or at 2 and 28 days o

74 nd ethically preferred until next-generation pertussis vaccines become available.

75 ve introduced adolescent and adult acellular pertussis vaccine boosters.

76 We have developed the live attenuated nasal pertussis vaccine BPZE1, currently undergoing clinical e

77 ons observed with diphtheria-tetanus toxoids-pertussis vaccine but has not eliminated the extensive s

78 s was true even prior to the introduction of pertussis vaccines but has become more pronounced since

79 netics of antibody responses to an acellular pertussis vaccine by a genome-wide association study in

80 east 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of age.

81 tive potential of the novel, live attenuated pertussis vaccine candidate BPZE1.

82 ntibody response induced by our epicutaneous Pertussis vaccine candidate containing non-adsorbed reco

83 Vaccination with whole-cell pertussis vaccine carries an increased risk of febrile s

84 Acellular pertussis vaccines combined with diphtheria and tetanus

85 unogenicity of 13 acellular and 2 whole cell pertussis vaccines combined with diphtheria and tetanus

86 ia-tetanus vaccine or the diphtheria-tetanus-pertussis vaccine compared with 77% and 58% usage, respe

87 erse events led the development of acellular pertussis vaccines containing 1 or more purified Bordete

88 he basis of current diphtheria, tetanus, and pertussis vaccine coverage and timing, a 90% efficacious

89 ted first- and third-dose diphtheria-tetanus-pertussis vaccine coverage in Borno state, Nigeria, usin

90 vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262,

91 ndations that older adults receive acellular pertussis vaccines, data on direct effectiveness in adul

92 ne immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2, DTP3, and measles

93 Case-patients having received at least 1 pertussis vaccine dose had a higher odds of having PRN(-

94 gests that the current schedule of acellular pertussis vaccine doses is insufficient to prevent outbr

95 pite high diphtheria, tetanus, and acellular pertussis vaccine (DTaP) coverage, indicating the possib

96 ffect of vaccination in the era of acellular pertussis vaccines (DTaP and Tdap), we assessed if vacci

97 eived different diphtheria-tetanus-acellular pertussis vaccines (DTaP) during childhood and should be

98 t dose of diphtheria and tetanus toxoids and pertussis vaccine (DTP 1) by 3 months of age failed to r

99 where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the fo

100 at the time of the first diphtheria-tetanus-pertussis vaccine (DTP1) or the first measles-containing

101 e of three doses of diphtheria, tetanus, and pertussis vaccine (DTP3) based on surveys using all avai

102 of GAVI on combined diphtheria, tetanus, and pertussis vaccine (DTP3) coverage.

103 ge with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-reported coverage a

104 nly (three doses of diphtheria, tetanus, and pertussis vaccines [DTP3] commencing in 1985, 1995, or 2

105 ered with diphtheria, tetanus, and acellular pertussis vaccine (dTpa) or placebo, and dTpa coadminist

106 it is not included in any current acellular pertussis vaccines due to protein stability issues and a

107 Children who received whole-cell pertussis vaccine during infancy or who received any per

108 analysis of published studies that evaluated pertussis vaccine efficacy or effectiveness within 3 yea

109 or more numerous booster doses of acellular pertussis vaccine either as part of routine immunization

110 seroprevalence data from the late whole-cell pertussis vaccine era in six European countries, we esti

111 Ensuring that children receive all doses of pertussis vaccine, even if there is some delay, is impor

112 ster with tetanus, diphtheria, and acellular pertussis vaccine for adolescents and adults) should be

113 me countries, nor from ones using whole-cell pertussis vaccines for primary immunization.

114 er, vaccine effect varies between individual pertussis vaccine formulations, and many originally stud

115 theria toxoid, tetanus toxoid, and acellular pertussis vaccine has been associated with some suppress

116 In Denmark, acellular pertussis vaccine has been included in the combined diph

117 ame time and vaccine studies showing that B. pertussis vaccines have little effect on B. parapertussi

118 ined thiomersal (diptheria-tetanus-acellular pertussis vaccine, hepatitis B vaccine, and in some chil

119 0 cases (17%) and 39 controls (71%) received pertussis vaccine in pregnancy.

120 We calculated the effectiveness of pertussis vaccine in preventing parapertussis among Oreg

121 the workshop "Overcoming Waning Immunity in Pertussis Vaccines" in September 2019 to identify issues

122 March 2000 (after introduction of acellular pertussis vaccine) in Ontario, Canada.

123 Many current acellular pertussis vaccines include the antigen pertactin, which

124 f pertussis after switching to the acellular pertussis vaccine, indicating a need for improved vaccin

125 accumulating literature on waning acellular pertussis vaccine-induced immunity, confirming the resul

126 ollowing routine vaccination with whole-cell pertussis vaccine, infants born to women receiving the T

127 t whether this risk applies to the acellular pertussis vaccine is not known.

128 evelopment of an effective infant Bordetella pertussis vaccine is urgently required because of the re

129 Duration of protection from pertussis vaccines is unclear because estimates vary by

130 global vaccination coverage with efficacious pertussis vaccines, it remains one of the least well-con

131 lysis of the short-term protective effect of pertussis vaccines limited to formulations currently on

132 ation-level safety benefits of the acellular pertussis vaccine may have been underestimated because o

133 Pertussis vaccine may induce cross-immunity.

134 Current acellular pertussis vaccines may not protect against transmission

135 nt population-level effects of the acellular pertussis vaccine on pertussis disease in addition to di

136 Impact of pertussis vaccines on mortality is a key World Health Or

137 fely profiles of combined IPV and whole-cell pertussis vaccines, OPV and whole-cell pertussis vaccine

138 ed either a dose of a tricomponent acellular pertussis vaccine or a hepatitis A vaccine (control) and

139 have had prolonged cough, immunization with pertussis vaccine, or treatment with erythromycin.

140 safety and cost-effectiveness of whole-cell pertussis vaccines, our study shows that, far from being

141 antenatal care programs to deliver maternal pertussis vaccines, particularly with respect to infants

142 Pertussis toxoid, an acellular pertussis vaccine prepared by hydrogen peroxide treatmen

143 alyzed 403 cases and 581 971 controls with 4 pertussis vaccines recorded.

144 Blunting of the infant pertussis vaccine response was detected in group B sibli

145 e effect of the vaccine on infant whole-cell pertussis vaccine responses.

146 scents and adults evaluated the incidence of pertussis, vaccine safety, immunogenicity, and protectiv

147 It appears that a wholly acellular pertussis vaccine series is significantly less effective

148 eks of age, before initiation of the primary pertussis vaccine series.

149 Dengue, tuberculosis, and pertussis vaccine-specific CD4(+) T cells were readily d

150 esponse and clinical protection conferred by pertussis vaccine, surveillance and a nested serosurvey

151 ncomitant tetanus, diphtheria, and acellular pertussis vaccine (Tdap) (GBS6 + Tdap), GBS6 and placebo

152 id, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered during pregnanc

153 anus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) could be an effective way of mi

154 iveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis among

155 n the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in persons aged >/=65 years are

156 mpared with the tetanus-diphtheria-acellular pertussis vaccine (Tdap).

157 iminated, by the presence of a sixth dose of pertussis vaccine (Tdap).

158 re personnel (HCP) vaccinated with acellular pertussis vaccine (Tdap).

159 ese adhesins are components of new acellular pertussis vaccines that have proven safe and highly effe

160 To overcome the limitations of the current pertussis vaccines, those of limited duration of action

161 nal or neonatal immunization, with acellular pertussis vaccines, to prevent life-threatening pertussi

162 children aged 7-18 months, VE for 3 doses of pertussis vaccine was 79% (95% confidence interval, 74%-

163 mmunization with a three-component acellular pertussis vaccine was characterized.

164 The acellular pertussis vaccine was protective among adolescents and a

165 ports from 1938 to 1955, when the whole-cell pertussis vaccine was rolled out, and related them to co

166 The acellular pertussis vaccine was safe and immunogenic.

167 ooster immunization of adults with acellular pertussis vaccines was not found to increase bactericida

168 id, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each

169 BPZE1, a live attenuated intranasal pertussis vaccine, was designed to prevent B pertussis i

170 infants vaccinated with ACPVs or whole cell pertussis vaccine (WCPV), and sera from patients with pe

171 , adult female baboons primed with acellular pertussis vaccine were boosted in the third trimester of

172 cases of encephalopathy following whole-cell pertussis vaccine were due to severe myoclonic epilepsy

173 d the third dose of diphtheria, tetanus, and pertussis vaccine were randomly assigned to receive meas

174 Childhood acellular pertussis vaccines were licensed and implemented in the

175 Acellular B. pertussis vaccines were not efficiently protective again

176 ll pertussis vaccines, and OPV and acellular pertussis vaccines were similar.

177 es (most commonly pneumococcal and acellular pertussis vaccines), whereas standalone IPV vaccines acc

178 which combines diphtheria-tetanus-whole cell pertussis vaccines with HbOC [Hib oligosaccharide CRM197

179 ed whether prior vaccination with whole-cell pertussis vaccine (wP) at any point provided superior pr